Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VCYT
vs
S&P 500
VCYT
S&P 500
Over the past 12 months, VCYT has underperformed S&P 500, delivering a return of +10% compared to S&P 500's +11% growth.
Stocks Performance
VCYT vs S&P 500
Performance Gap
VCYT vs S&P 500
Performance By Year
VCYT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Veracyte Inc
Glance View
Veracyte is a molecular diagnostics company that makes lab tests doctors use to help diagnose cancer and other serious diseases. Its tests analyze genetic and other biological signals from patient samples, such as tissue or blood, to give more useful answers than traditional methods alone. The company sells these tests to hospitals, doctors, and labs that need better information to guide care. Its main business is selling diagnostic tests and the related lab services that produce the results. Veracyte earns money when its tests are ordered and processed, usually through reimbursement from health plans, government programs, or direct payment from healthcare customers. In practice, it sits between the patient sample and the treatment decision, turning complex biology into a clearer clinical report. What makes Veracyte different is that it focuses on tests that can reduce uncertainty in tough cases, especially when doctors are deciding whether a lump, lesion, or other finding is harmless or cancerous. That kind of test can help avoid unnecessary procedures or speed up the right next step in care. Its business depends on building tests that doctors trust and that fit into standard medical workflows.
